Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2005

View Archived Issues

Nimotuzumab reported to increase response to radiotherapy in nasopharyngeal carcinoma

New data from the STRIDE-4 trial supports the use of Thelin in PAH

Mologen and IDRI sign collaboration agreement

NDA submission for Seasonique extended-cycle oral contraceptive

USAMRIID awards grant to Lexicon for ricin biodefense efforts

Novartis ramps up Coartem production

Phase III trial for Remoxy

Enrollment completed in phase II congestive heart failure study of oxypurinol

Liposomes for use as contrast medium

Kinase inhibitors claimed by Merck

Scientists at Kyorin prepare and test a series of immunosuppressants

Novel PDE4 inhibitors in early development at Memory

Agents for migraine described by Lilly

Synthesis and biological activity of YM-92088, a novel nonsteroidal androgen receptor antagonist

Insmed completes SomatoKine NDA

Neuro3d completes third round of financing to fund pipeline development

New River and Shire sign letter of intent for ADHD drug NRP-104

Matriptase inhibitor suppresses androgen-independent prostate cancer in vitro and in vivo

Donepezil reported to improve cognition and memory in early-stage Alzheimer's disease

Update on the effects and safety of ABI-007 in breast cancer

Characterization of novel, selective phosphodiesterase type 7 inhibitor BRL-50481

AEE-788 shows promise in the treatment of breast cancer

Novel H3 antagonist demonstrates wake-promoting effects

Heparin sulphate mimetics prolong survival of laboratory animals with prion diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...